Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing Infi-Symphytum (Calcium Carbonicum) acetate therapy. More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Should hypercalcemia develop, reduce the Infi-Symphytum (Calcium Carbonicum) acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia Therefore, early in the treatment phase during the dosage adjustment period, monitor serum Infi-Symphytum (Calcium Carbonicum) levels twice weekly. Avoid the use of Infi-Symphytum (Calcium Carbonicum) supplements, including Infi-Symphytum (Calcium Carbonicum) based nonprescription antacids, concurrently with Infi-Symphytum (Calcium Carbonicum) acetate.Īn overdose of Infi-Symphytum (Calcium Carbonicum) acetate may lead to progressive hypercalcemia, which may require emergency measures. Patients with end stage renal disease may develop hypercalcemia when treated with Infi-Symphytum (Calcium Carbonicum), including Infi-Symphytum (Calcium Carbonicum) acetate. Hypercalcemia may aggravate digitalis toxicity. Severe hypercalcemia may require hemodialysis and discontinuation of Infi-Symphytum (Calcium Carbonicum) acetate. Treat mild hypercalcemia by reducing or interrupting Infi-Symphytum acetate and Vitamin D. Capsule: 667 mg Infi-Symphytum (Calcium Carbonicum) acetate capsule. (2)Ĭapsule: 667 mg Infi-Symphytum (Calcium Carbonicum) acetate capsule. Most patients require 3 to 4 capsules with each meal.
Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Starting dose is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. The recommended initial dose of Infi-Symphytum (Calcium Carbonicum) acetate for the adult dialysis patient is 2 capsules with each meal. Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. Infi-Symphytum (Calcium Carbonicum) acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).